Insulin management for patients in the neurocritical care unit with aSAH is challenging as hypoglycemia, hyperglycemia, and intensive insulin therapy (targets 81–108 mg/dL) have all been associated with higher mortality and increased complications25–27. This evidence concerns the gene INS and Hyperglycemia.